|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
9 January 2017 |
|
Main ID: |
NCT02462395 |
|
Date of registration:
|
27/05/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache
ANODECCH |
|
Scientific title:
|
Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Chronic Cluster Headache: a Pilot Trial. |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
32 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02462395 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 2/Phase 3
|
|
|
Countries of recruitment
|
|
Belgium
| | | | | | | |
|
Contacts
|
|
Name:
|
Delphine Magis, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Liege |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Main inclusion criteria for CCH: preventive CH therapy stable for a least 2 months,
retrospective 4-week headache baseline diary showing at least 4 attacks/week on
average
Exclusion Criteria:
- No other significant medical or psychiatric disease.
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Cluster Headache
|
|
Intervention(s)
|
|
Device: tDCS
|
|
Primary Outcome(s)
|
|
Reduction of weekly cluster headache attack frequency during and following tDCS treatment in CCH patients.
[Time Frame: 4 to 8 weeks]
|
|
Secondary Outcome(s)
|
|
modification of the nociceptive blink reflex
[Time Frame: 4 to 8 weeks]
|
|
reduction of duration of CH attacks
[Time Frame: 4 to 8 weeks]
|
|
modification of pain thresholds
[Time Frame: 4 to 8 weeks]
|
|
reduction of acute medication intake
[Time Frame: 4 to 8 weeks]
|
|
reduction of intensity of CH attacks
[Time Frame: 4 to 8 weeks]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|